Newer approaches for optimal bioavailability of ocularly delivered drugs: Review

Current Drug Delivery

Volumn 8, Issue 2, 2011, Pages 172-193

  Kesavan, K ^a   Balasubramaniam, J ^b   Kant, S ^c   Singh, P N ^a   Pandit, J K ^a  

^a BANARAS HINDU UNIVERSITY   (India)

^b RA Chem Pharma Limited   (India)

^c BANARAS HINDU UNIVERSITY   (India)

Author keywords

Biocompatibility; In situ gelling system; Nanoparticulate system; Ocular insert; Ocular sustained drug delivery; Scleral implants; Vitreous implants

Indexed keywords

ALGINIC ACID; CARBOMER; CARTEOLOL; CIPROFLOXACIN; COLLAGEN; CYCLOSPORIN A; DENDRIMER; DEXAMETHASONE; DICLOFENAC; EPIDERMAL GROWTH FACTOR; FLUORESCEIN; FOSCARNET; GANCICLOVIR; GATIFLOXACIN; GELLAN; GENTAMICIN; HYDROXYPROPYLMETHYLCELLULOSE; INDOMETACIN; LIPOSOME; OFLOXACIN; OXYTETRACYCLINE; PEFLOXACIN MESILATE; PILOCARPINE; POLOXAMER; POLYMER; PREDNISOLONE; TILISOLOL; TIMOLOL MALEATE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AREA UNDER THE CURVE; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABLE IMPLANT; BLEPHARITIS; CLASSIFICATION; CONJUNCTIVA; CORNEA; CYTOMEGALOVIRUS RETINITIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG PENETRATION; EYE DISEASE; EYE INFECTION; GLAUCOMA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMPLANT; MICROEMULSION; OPTICAL INSTRUMENTATION; PRIORITY JOURNAL; SCLERA; TEMPERATURE DEPENDENCE; UNSPECIFIED SIDE EFFECT; UVEITIS; VITREOUS BODY;

ANIMALS; BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; EYE; HUMANS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TECHNOLOGY, PHARMACEUTICAL;

EID: 79551628682     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720111794479925     Document Type: Article

References (167)

1. Meqi, S.A.; Deshpande, S.G. Ocular drug delivery. In: Jain, N.K., Ed., Controlled and novel drug delivery, CBS Publishers, New Delhi, 2002; pp. 82-84.
2. Lee, V.H.L.; Robinson, J.R. Mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits. J. Pharm. Sci., 1979, 68, 673-684.
3. Maurice, D.M.; Mishima, S. Ocular pharmacokinetics. In: Sears, M.C., Ed., Handbook of Experimental Pharmacology. Pharmacology of the Eye. Springer-Verlag, Berlin-Heidelberg, 1984; Vol. 69, pp. 19-l16.
4. Maurice, D.M. Kinetics of topically applied drugs. In: Ophthalmic Drug Delivery: Biopharmaceutical, Technological and Clinical Aspects, In: Saettone, M. S., Bucci, P., and Speiser, P., Padova: Fidia Research Series, Liviana Press, 1987; Vol. 11, pp. 19-26.
5. Schoenwald, R.D. Ocular drug delivery: pharmacokinetic considerations. Clin. Pharmacokinet., 1990, 18(4), 255-269.
6. Middleton, D.L.; Leung, S.S.; Robinson, J.R. Bioadhesive Drug Delivery Systems, In: Lenaerts, V., and Gurny, R., Boca Raton, FL: CRC Press, 1990; pp. 179-202.
7. Schoenwald, R.D.; Ward, R.L.; DeSantis, L.M.; Rochrs, R.E. Influence of high viscosity vehicles on miotic effect of pilocarpine. J. Pharm. Sci. 1978, 67(9), 1280-1284.
8. Maurice, D.M.; Srinivas, S.D. Use of fluorometry in assessing the efficacy of a cation sensitive gel as an ophthalmic vehicle: comparison with scintigraphy. J. Pharm. Sci. 1992, 81(7), 615-619.
9. Bourlais, C.L.; Acar, L.; Zia, H.; Sado, P.A.; Needham, T.; Leverge, R. Ophthalmic drug delivery systems-recent advances. Prog. Retinal Eye Res., 1998, 17(1), 33-58.
10. Ding, S. Recent developments in ophthalmic drug delivery. Pharm. Sci. Technol. Today, 1998, 1, 328-335.
11. Bito, L.Z. Transport functions of the blood-ocular and blood-brain barriers, and the micro environment of neuronal and non-neuronal tissues: In Barriers and fluids of the eye and brain. In: Segal, M.B.; Ed CRC press, Boca Raton, 1992.
12. Refojo, M.F. Polymers in contact lenses: An over review. Curr. Eye Res., 1985, 4, 719-723.
13. Alvarez-Lorenzo, C.; Hiratani, H.; Gomez-Amoza, J.L.; Martinez-Pacheco, R.; Souto, C.; Concheiro, A. Soft contact lenses capable of sustained delivery of timolol. J. Pharm. Sci., 2002, 91(10), 2182-2192.
14. Hiratani, H.; Alvarez-Lorenzo, C. Timolol uptake and release by imprinted soft contact lenses made of N,N-diethylacrylamide and methacrylic acid. J. Control. Release, 2002, 83(2), 223-230.
15. Hiratani, H.; Alvarez-Lorenzo, C. The nature of backbone monomers determines the performance of imprinted soft contact lenses as timolol drug delivery systems. Biomaterials, 2004, 25(6), 1105-1113.
16. Kikic, I.; Vecchione, F. Supercritical impregnation of polymers. Curr. Opin. Solid State Mater. Sci., 2003, 7, 399-405.
17. Elvira, C.; Fanovich, A.; Fernandez, M.; Fraile, J.; San Roman, J.; Domingo, C. Evaluation of drug delivery characteristics of microspheres of PMMAPCL- Cholesterol obtained by supercritical CO2 impregnation and by dissolution-evaporation techniques. J. Control. Release, 2004, 99(2), 231-240.
18. Kikic, I.; Sist, P. Applications of supercritical fluids to pharmaceuticals: controlled drug delivery systems, supercritical fluids: fundamentals and applications, in: Proceedings of the Second NATO ASI on Supercritical Fluids, NATO Science Series, Kluwer Academic Publishers, Dordrecht, The Netherlands, 2000, pp. 291-306.
19. Berens, A.R.; Huvard, G.S.; Korsmeyer, R.W.; Kunig, F.W. Application of compressed carbon dioxide in the incorporation of additives into polymers. J. Appl. Polym. Sci., 1992, 46(2), 231-242.
20. Kazarian, S.G. Supercritical Fluid Impregnation of Polymers for Drug Delivery, Supercritical Fluid Technology for Drug Product Development, Marcel Dekker, Inc., USA, 2004, p. 343.
21. Fleming, O.S.; Kazarian, S.G. Polymer Processing with Supercritical Fluids, In: Kemmere, M.F.; Meyer, T., Eds., Supercritical Carbon Dioxide: in Polymer Reaction Engineering, Wiley-VCH Verlag GmbH & Co, Weinheim, Germany, 2005, pp. 205-234.
22. Di Colo, G.; Zambito, Y. A study of release mechanisms of different ophthalmic drugs from erodible ocular inserts based on poly (ethylene oxide). Eur. J. Pharm. Biopharm., 2002, 54, 193-199.
23. Koelwel, C.; Rothschenk, S.; Fuchs-Koelwel, B.; Gabler, B.; Lohmann, C.; Gopferich, A. Alginate inserts loaded with epidermal growth factor for the treatment of keratoconjunctivitis sicca. Pharm. Dev. Tech., 2008, 13(3), 221-231.
24. Baeyens, V.; Felt-Baeyens, O.; Rougier, S.; Pheulpin, S.; Boisramé, B.; Gurny, R. Clinical evaluation of bioadhesive ophthalmic drug inserts (BODI) for the treatment of external ocular infections in dogs. J. Control. Release, 2002, 85, 163-168.
25. Kawakami, S.; Nishida, K.; Mukai, T.; Yamamura, K.; Nakamura, J.; Sakaeda, T.; Nakashima, M.; Sasaki, H. Controlled release and ocular absorption of tilisolol utilizing ophthalmic insertincorporated lipophilic prodrugs. J. Control. Release, 2001, 76, 255-263.
26. Natu, M.V.; Sardinha, J.P.; Correia, I.J.; Gil, M.H. Controlled release gelatin hydrogels and lyophilisates with potential application as ocular inserts. Biomed. Mater., 2007, 2, 241-249.
27. Gorle, A.P.; Gattani, S.G. Design and Evaluation of Polymeric Ocular Drug Delivery System. Chem. Pharm. Bull., 2009, 57(9), 914-919.
28. Mundada, A.S.; Shrikhande, B.K. Design and evaluation of soluble ocular drug insert for controlled release of ciprofloxacin hydrochloride. Drug Dev. Ind. Pharm., 2006, 32, 443-448.
29. Di Colo, G.; Zambito, Y.; Burgalassi, S.; Serafini, A.; Saettone, M.F. Effect of chitosan on in vitro release and ocular delivery of ofloxacin from erodible inserts based on poly (ethylene oxide). Int. J. Pharm., 2002, 248, 115-122.
30. Mundada, A.S.; Shrikhande, B.K. Formulation and evaluation of ciprofloxacin hydrochloride soluble ocular drug insert. Curr. Eye Res., 2008, 33(5), 469-475.
31. Di Colo, G.; Burgalassi, S.; Chetoni, P.; Fiaschi, M.P.; Zambito, Y.; Saettone, M.F. Gel-forming erodible inserts for ocular controlled delivery of ofloxacin. Int. J. Pharm., 2001, 215, 101-111.
32. Tanwar, Y.S.; Patel, D.; Sisodia, S.S. In vitro and in vivo evaluation of ocular inserts of ofloxacin. DARU, 2007, 15(3), 139-145.
33. Balasubramaniam, J.; Srinatha, A.; Pandit, J.K.; Nath, G. In vitro microbiological evaluation of polyvinyl alcohol based ocular inserts of ciprofloxacin hydrochloride. Indian J. Pharm. Sci., 2006, 68(5), 626-630.
34. Hornof, M.; Weyenberg, W.; Ludwig, A.; Schnürch, A.B. Mucoadhesive ocular insert based on thiolated poly (acrylic acid): development and in vivo evaluation in humans. J. Control. Release, 2003, 89, 419-428.
35. Sultana, Y.; Aqil, M.; Ali, A. Ocular inserts for controlled delivery of pefloxacin mesylate: Preparation and evaluation. Acta Pharm., 2005, 55, 305-314.
36. Sreenivas, S.A.; Hiremath, S.P.; Godbole, A.M. Ofloxacin ocular insert: design formulation and evaluation. Iranian J. Pharmacol. Ther., 2006, 5(2), 159-162.
37. Charoo, N.A.; Kohli, K.; Ali, A.; Anwer, A. Ophthalmic delivery of ciprofloxacin hydrochloride from different polymer formulations: in vitro and in vivo studies. Drug Dev. Ind. Pharm., 2003, 29 (2), 215-221.
38. El-Kamel, A.H. In vitro and in vivo evaluation of Pluronic F127- based ocular delivery system for timolol maleate. Int. J. Pharm., 2002, 241, 47-55.
39. Gurny, R.; Ibrahim, H.; Buri, P.; Edman, P. In: Biopharmaceutics of ocular drug delivery. CRC Press, London, 1993; pp. 81.
40. Srividya, B.; Cardoza, R.M.; Amin, P.D. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J. Control. Release, 2001, 73, 205-211.
41. Jain, S.P.; Shah, S.P.; Rajadhyaksha, N.S.; Singh, P.S.P.P.; Amin, P.D. In situ ophthalmic gel of ciprofloxacin hydrochloride for once a day sustained delivery. Drug Dev. Ind. Pharm., 2008, 34(4), 445-452.
42. Kumar, S.; Himmelstein, K.J. Modification of in Situ Gelling Behavior of Carbopol Solutions by Hydroxypropyl Methylcellulose. J. Pharm. Sci., 1995, 84(3), 344-348.
43. Wu, C.; Qi, H.; Chen, W.; Huang, C.; Su, C.; Li, W.; Hou, S. Preparation and evaluation of a carbopol/HPMC based in situ gelling ophthalmic system for puerarin. Yakugaku Zasshi, 2007, 127(1), 183-191.
44. Liu, Z.; Pan, W.; Nie, S.; Zhang, L.; Yang, X.; Li, J. Preparation and evaluation of sustained ophthalmic gel of enoxacin. Drug Dev. Ind. Pharm., 2005, 31, 969-975.
45. Hoffman, A.S.; Afrassiabi, A.; Dong, L.C. Thermally reversible hydrogels: II. Delivery and selective removal of substances from aqueous solutions. J. Control. Release, 1986, 4, 213-222.
46. Furrer, P.; Plazonnet, B.; Mayer, J.M.; Gurny, R. Application of in vivo confocal microscopy to the objective evaluation of ocular irritation induced by surfactants. Int. J. Pharm., 2000, 207(1-2), 89-98.
47. Ma, W.D.; Xu, H.; Wang, C.; Nie, S.F.; Pan, W.S. Pluronic F127- g-poly (acrylic acid) copolymers as in situ gelling vehicle for ophthalmic drug delivery system. Int. J. Pharm., 2008, 350, 247-256.
48. Ma, W.D.; Xu, H.; Nie, S.F.; Pan, W.S. Temperature-Responsive, Pluronic-g-poly (acrylic acid) Copolymers in Situ Gels for Ophthalmic Drug Delivery: Rheology, In Vitro Drug Release, and In Vivo Resident Property. Drug Dev. Ind. Pharm., 2008, 34, 258-266.
49. Mansour, M.; Mansour, S.; Mortada, N.D.; Abd Elhady, S.S. Ocular poloxamer based ciprofloxacin hydrochloride in situ forming gels. Drug Dev. Ind. Pharm., 2008, 34, 744-752.
50. Kim, E.Y.; Gao, Z.G.; Park, J.S.; Li, H.; Han, K. rhEGF/HP- -CD complex in poloxamer gel for ophthalmic delivery. Int. J. Pharm., 2000, 233, 159-167.
51. Qi, H.; Chen, W.; Huang, C.; Li, L.; Chen, C.; Li, W.; Wu, C. Development of a poloxamer analogs/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. Int. J. Pharm., 2007, 337, 178-187.
52. Wei, G.; Xu, H.; Ding, P.T.; Li, S.M.; Zheng, J.M. Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies. J. Control. Release, 2002, 83(1), 65-74.
53. Miyazaki, S.; Suzuki, S.; Kawasaki, N.; Endo, K.; Takahashi, A.; Attwood, D. In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int. J. Pharm., 2001, 229, 29-36.
54. Kaur, I.P.; Singh, M.; Kanwar, M. Formulation and evaluation of ophthalmic preparations of acetazolamide. Int. J. Pharm., 2000, 199(2), 119-127.
55. Felt, O.; Buri, P.; Gurny, R. Chitosan: a unique polysaccharide for drug delivery. Drug Dev. Ind. Pharm., 1998, 24(11), 979-993.
56. Illum, L. Chitosan and its use as a pharmaceutical excipient. Pharm. Res., 1998, 15(9), 1326-1331.
57. Singla, A.K.; Chawla, M. Chitosan: some pharmaceutical and biological aspects--an update. J. Pharm. Pharmacol., 2001, 53(8), 1047-1067.
58. Alonso, M.J.; Sanchez, A. The potential of chitosan in ocular drug delivery. J. Pharm. Pharmacol., 2003, 55(11), 1451-1463.
59. Cao, Y.; Zhang, C.; Shen, W.; Cheng, Z.; Yu, L.; Ping, Q. Poly (N- isopropylacrylamide)-chitosan as thermosensitive in situ gelforming system for ocular drug delivery. J. Control. Release, 2007, 120, 186-194.
60. Ruel, G.E.; Chenite, A.; Chaput, C.; Guirguis, S.; Leroux, J. Characterization of thermosensitive chitosan gels for the sustained delivery of drugs. Int. J. Pharm., 2000, 203(1-2), 89-98.
61. Krauland, A.H.; Hoffer, M.H.; Bernkop-Schnürch, A. Viscoelastic properties of a new in situ gelling thiolated chitosan conjugate. Drug Dev. Ind. Pharm., 2005, 31, 885-893.
62. Gupta, H.; Jain, S.; Mathur, R.; Mishra, P.; Mishra, A.K.; Velpandian, T. Sustained ocular drug delivery from a temperature and ph triggered novel in situ gel system. Drug Deliv., 2007, 14, 507-515.
63. Sultana, Y.; Aqil, M.; Ali, A.; Zafar, S. Evaluation of carbopolmethyl cellulose based sustained-release ocular delivery system for pefloxacin mesylate using rabbit eye model. Pharm. Dev. Tech., 2006, 11, 313-319.
64. Lin, H.R.; Sung, K.C. Carbopol/pluronic phase change solutions for ophthalmic drug delivery. J. Control. Release, 2000, 69(3), 379-388.
65. Jansson, P.E.; Lindberg, B.; Sandford, P.A. Structural studies of gellan gum, an extracellular polysaccharide elaborated by Pseudomonas elodea. Carbohydr. Res., 1983, 124(1), 135-139.
66. Kuo, M.S.; Mort, A.J.; Dell, A. Identification and location of -glycerate, an unusual acyl substituent in gellan gum. Carbohydr. Res., 1986, 156, 173-187.
67. Morris, V.J. Bacterial polysaccharides. In: Stephen, A.M., Ed., Food polysaccharides and their applications. New York: Marcel Dekker, 1995; pp. 341-375.
68. Suri, S.; Banerjee, R. In vitro evaluation of in situ gels as short term vitreous substitutes. J. Biomed. Mater. Res. A, 2006, 79(3), 650-664.
69. El-Kamel, A.; Al-Dosari, H.; Al-Jenoobi, F. Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride. Drug Deliv., 2006, 13, 55-59.
70. Balasubramaniam, J.; Pandit, J.K. Ion-activated in situ gelling systems for sustained ophthalmic delivery of ciprofloxacin hydrochloride. Drug Deliv., 2003, 10, 185-191.
71. ® gellan gum-based ocular delivery system for indomethacin. Acta Pharm., 2003, 53, 251-261.
72. Hassan, A.M. A long acting ophthalmic gel formulations of atenolol. Drug Dev. Ind. Pharm., 2007, 33, 1192-1198.
73. Liu, Z.; Yang, X.G.; Li, X.; Pan, W.; Li, J. Study on the Ocular Pharmacokinetics of Ion-Activated in Situ Gelling Ophthalmic Delivery System for Gatifloxacin by Microdialysis. Drug Dev. Ind. Pharm., 2007, 33, 1327-1331.
74. Sultana, Y.; Aqil, M.; Ali, A. Ion-activated, gelrite based in situ ophthalmic gels of pefloxacin mesylate: comparison with conventional eye drops. Drug Deliv., 2006, 13, 215-219.
75. Liu, Z.; Li, J.; Nie, S.; Liu, H.; Ding, P.; Pan, W. Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int. J. Pharm., 2006, 315, 12-17.
76. Doijad, R.C.; Manvi, F.V.; Rao, V.S.N.M.; Alase, P. Sustained ophthalmic delivery of gatifloxacin from in situ gelling system. Indian J. pharm. Sci., 2006, 68(6), 814-818.
77. Lin, H.R.; Sung, K.C.; Vong, W.J. In Situ Gelling of Alginate/Pluronic Solutions for Ophthalmic Delivery of Pilocarpine. Biomacromolecules, 2004, 5, 2358-2365.
78. Sechoy, O.; Tissié, G.; Sébastian, C.; Maurin, F.; Driot, J.Y.; Trinquand, C. A new long acting ophthalmic formulation of Carteolol containing alginic acid. Int. J. Pharm., 2000, 207, 109-116.
79. Musch, D.C.; Martin, D.F.; Gordon, J.; Davis, M.D.; Kuppermann, B.D. Ganciclovir implant study group: treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N. Engl. J. Med., 1997, 337(2), 83-90.
80. Sanborn, G.E.; Anand, R.; Torti, R.; Nightingale, S.D.; Cal, S.X.; Yates, B.; Ashton, P.; Smith, T.J. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Arch. Ophthalmol., 1992, 110, 188-195.
81. Kimura, H.; Ogura, Y. Biodegradable polymers for ocular drug delivery. Ophthalmologica, 2001, 215, 143-155.
82. Yasukawa, T.; Ogura, Y.; Sakurai, E. Intraocular sustained drug delivery using implantable polymeric devices. Adv. Drug Deliv. Rev., 2005, 57(14), 2033-2046.
83. Alikacem, N.; Yoshizawa, T.; Nelson, K.D. Quantitative MR imaging study of intravitreal sustained release of VEGF in rabbits. Invest. Ophthalmol. Vis. Sci., 2000, 41(6), 1561-1569.
84. Beeley, N.R.; Rossi, J.V.; MeIlo-Filho, P.A. Fabrication, implantation, elution, and retrieval of a steroid-loaded polycaprolactone subretinal implant. J. Biomed. Mater. Res. A, 2005, 73(4), 437-444.
85. Haesslein, A.; Ueda, H.; Hacker, M.C. Long-term release of fluocinolone acetonide using biodegradable fumarate-based polymers. J. Control. Release, 2006, 114(2), 251-260.
86. Heller, J. Ocular delivery using poly (ortho esters). Adv. Drug Deliv. Rev., 2005, 57(14), 2053-2062.
87. Eperon, S.; Bossy-Nobs, L.; Petropoulos, I.K.; Gurny, R.; GuexCrosier, Y. A biodegradable drug delivery system for the treatment of postoperative inflammation. Int. J. Pharm., 2008, 352, 240-247.
88. Gilger, B.C.; Salmon, J.H.; Wilkie, D.A.; Cruysberg, L.P.; Kim, J.; Hayat, M.; Kim, H.; Kim, S.; Yuan, P.; Lee, S.S.; Harrington, S.M.; Murray, P.R.; Edelhauser, H.F.; Csaky, K.G.; Robinson, M.R. A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis. Invest. Ophthalmol. Vis. Sci., 2006, 47, 2596-2605.
89. Kim, Y.M.; Lim, J.O.; Kim, H.K.; Kim, S.Y.; Shin, J.P. A novel design of one-side coated biodegradable intrascleral implant for the sustained release of triamcinolone acetonide. Eur. J. Pharm. Biopharm., 2008, 70, 179-186.
90. Felt-Baeyens, O.; Eperon, S.; Mora, P.; Limal, D.; Sagodira, S.; Breton, P.; Simonazzi, B.; Bossy-Nobs, L.; Guex-Crosier, Y.; Gurny, R. Biodegradable scleral implants as new triamcinolone acetonide delivery systems. Int. J. Pharm., 2006, 322, 6-12.
91. Fialho, S.L.; Behar-Cohen, F.; Silva-Cunha, A. Dexamethasone-loaded poly(-caprolactone) intravitreal implants: A pilot study. Eur. J. Pharm. Biopharm., 2008, 68, 637-646.
92. Misra, G.P.; Singh, R.S.J.; Aleman, T.S.; Jacobson, S.G.; Gardner, T.W.; Lowe, T.L. Subconjunctivally implantable hydrogels with degradable and thermoresponsive properties for sustained release of insulin to the retina. Biomaterials, 2009, 30, 6541-6547.
93. Peng, Y.J.; Wen, C.W.; Chiou, S.H.; Liu, S.J. Sustained release of ganciclovir and foscarnet from biodegradable scleral plugs for the treatment of cytomegalovirus retinitis. Biomaterials, 2010, 31, 1773-1779.
94. Okabe, J.; Kimura, H.; Kunou, N.; Okabe, K.; Kato, A.; Ogura, Y. Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Invest. Ophthalmol. Vis. Sci., 2003, 44, 740-744.
95. Kunou, N.; Ogura, Y.; Honda, Y.; Hyon, S.H.; Ikada, Y. Biodegradable scleral implant for controlled intraocular delivery of betamethasone phosphate. J. Biomed. Mater. Res., 2000, 51, 635-641.
96. Ciulla, T.A.; Criswell, M.H.; Danis, R.P.; Fronheiser, M.; Yuan, P.; Cox, T.A.; Csaky, K.G.; Robinson, M.R. Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants. Br. J. Ophthalmol., 2003, 87, 1032-1037.
97. Kumar, M.T.; Rajeswari, C.; Balasubramaniam, J.; Pandit, J.K. In vitro and in vivo characterization of scleral implant of indomethacin: role of plasticizer and cross-linking time. Drug Deliv., 2003, 10, 269-275.
98. Balasubramaniam, J.; Kumar, M.T.; Pandit, J.K. Gellan-based scleral implants of indomethacin: in vitro and in vivo evaluation. Drug Deliv., 2004, 11, 371-379.
99. Hamidi, M.; Azadi, A.; Rafiei, P. Hydrogel nanoparticles in drug delivery. Adv. Drug Deliv. Rev., 2008, 60, 1638-1649.
100. Sahoo, S.K.; Labhasetwar, V. Nanotech approaches to drug delivery and imaging. Drug Discov. Today. 2003, 8, 1112-1120.
101. Sahoo, S.K.; Dilnawaz, F.; Krishnakumar, S. Nanotechnology in ocular drug delivery. Drug Discov. Today. 2008, 13, 144-150.
102. Vasir, J.K.; Reddy, M.K.; Labhasetwar, V. Nanosystems in drug targeting: opportunities and challenges. Curr. Nanosci., 2005, 1, 47-64.
103. Ludwig, A. The use of mucoadhesive polymers in ocular drug delivery, Adv. Drug Deliv. Rev., 2005, 57, 1595-1639.
104. Badawi, A.A.; El-Laithy, H.M.; El Qidra, R.K.; El Mofty, H.; El Dally, M. Chitosan based nanocarriers for indomethacin ocular delivery. Arch. Pharm. Res., 2008, 31, 1040-1049.
105. Pignatello, R.; Bucolo C.; Puglisi, G. Ocular tolerability of Eudragit RS100 and RL100 nanosuspensions as carriers for ophthalmic controlled drug delivery. J. Pharm. Sci., 2002, 91, 2636-2641.
106. Pignatello, R.; Bucolo, C.; Ferrara, P.; Maltese, A.; Puleo, A.; Puglisi, G. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur. J. Pharm. Sci., 2002, 16, 53-61.
107. Pignatello, R.; Bucolo, C.; Spedalieri, G.; Maltese, A.; Puglisi, G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials, 2002, 23, 3247-3255.
108. Adibkia, K.; Siahi Shadbad, M.R.; Nokhodchi, A.; Javadzedeh, A.; Barzegar-Jalali, M.; Barar, J. Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin induced uveitis. J. Drug Target., 2007, 15, 407-416.
109. Vega, E.; Egea, M.A.; Valls, O.; Espina, M.; Garcia, M.L. Flurbiprofen loaded biodegradable nanoparticles for ophthalmic administration. J. Pharm. Sci., 2006, 95, 2393-2405.
110. Gomez-Gaete, C.; Tsapis, N.; Besnard, M.; Bochot, A.; Fattal, E. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int. J. Pharm., 2007, 331, 153-159.
111. Tenjarla, S. Microemulsions: an overview and pharmaceutical applications. Crit. Rev. Ther. Drug Carrier Syst., 1999, 16, 461-521.
112. Silva-Cunha, A.; Fialho, S.L.; Carneiro, L.B.; Oréfice, F. Microemulsões como veículos de drogas para administração ocular tópica. Arq. Bras. Oftalmol., 2003, 66, 385-391.
113. Kapoor, Y.; Chauhan, A. Ophthalmic delivery of Cyclosporine A from Brij-97 microemulsion and surfactant-laden p-HEMA hydrogels. Int. J. Pharm., 2008, 361, 222-229.
114. Chan, J.; Maghraby, G.M.; Craig, J.P.; Alany, R.G. Phase transition water-in-oil microemulsions as ocular drug delivery systems: In vitro and in vivo evaluation. Int. J. Pharm., 2007, 328, 65-71.
115. Lv, F.F.; Zheng, L.Q.; Tung, C.H. Phase behavior of the microe-mulsions and the stability of the chloramphenicol in the microe-mulsion-based ocular drug delivery system. Int. J. Pharm., 2005, 301, 237-246.
116. Gan, L.; Gan, Y.; Zhu, C.; Zhang, X.; Zhu, J. Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: in vitro and in vivo results. Int. J. Pharm., 2009, 365(1-2), 143-149.
117. Fialho, S.L.; da Silva-Cunha, A. New vehicle based on a microe-mulsion for topical ocular administration of dexamethasone. Clin. Exp. Ophthalmol., 2004, 32, 626-632.
118. Hosny, K.M. Ciprofloxacin as ocular liposomal hydrogel. AAPS Pharm. Sci. Tech., 2010, 11(1), 241-246.
119. Budai, L.; Hajdú, M.; Budai, M.; Gróf, P.; Béni, S.; Noszál, B.; Klebovich, I.; Antal, I. Gels and liposomes in optimized ocular drug delivery: studies on ciprofloxacin formulations. Int. J. Pharm., 2007, 343(1-2), 34-40.
120. Hosny, K.M. Preparation and evaluation of thermosensitive liposomal hydrogel for enhanced transcorneal permeation of ofloxacin. AAPS Pharm. Sci. Tech., 2009, 10(4), 1336-1342.
121. Mehanna, M.M.; Elmaradny, H.A.; Samaha, M.W. Mucoadhesive liposomes as ocular delivery system: physical, microbiological, and in vivo assessment. Drug. Dev. Ind. Pharm., 2010, 36(1), 108-118.
122. Li, N.; Zhuang, C.; Wang, M.; Sun, X.; Nie, S.; Pan, W. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. Int. J. Pharm., 2009, 379(1), 131-138.
123. Vandamme, Th.F.; Brobeck, L. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J. Control. Release, 2005, 102: 23-38.
124. Milhem, O.M.; Myles, C.; Keown, N.B.M.; Attwood, D.; Emanuelle, A.D. Polyamidoamine Starburst dendrimers as solubility enhancers, Int. J. Pharm., 2000, 197, 239-241.
125. Bhadra, D.; Bhadra, S.; Jain, S.; Jain, N.K. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int. J. Pharm., 2003, 257, 111-124.
126. Ooya, T.; Lee, J.; Park, K. Effects of ethylene glycol based graft, star-shaped, and dendritic polymers on solubilization and controlled release of placlitaxel, J. Control. Release. 2003, 93, 121-127.
127. Grinstaff, M.W. Designing hydrogel adhesives for corneal wound repair. Biomaterials, 2007, 28, 5205-5214.
128. Calabretta, M.K.; Kumar, A.; McDermott, A.M.; Cai, C. Antibacterial activities of poly(amidoamine) dendrimers terminated with amino and poly(ethylene glycol) groups. Biomacromolecules, 2007, 8(6), 1807-1811.
129. Cavalli, R.; Gasco, M.R.; Chetoni, P.; Burgalassi, S.; Saettone, M.F. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int. J. Pharm., 2002, 238(1-2), 241-245.
130. Friedrich, I.; Reichl, S.; Müller-Goymann, C.C. Drug release and permeation studies of nanosuspensions based on solidified reverse micellar solutions (SRMS). Int. J. Pharm., 2005, 305(1-2), 167-175.
131. Attama, A.A.; Reichl, S.; Muller-Goymann, C.C. Diclofenac sodium delivery to the eye: In vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int. J. Pharm., 2008, 355(1-2), 307-313.
132. Souto, E.B.; Muller, R.H. Lipid nanoparticles: effect on bioavail-ability and pharmacokinetic changes. Handb. Exp. Pharmacol., 2010, 197, 115-141.
133. Araújo, J.; Gonzalez-Mira, E.; Egea, M.A.; Garcia, M.L.; Souto, E.B. Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int. J. Pharm., 2010, 393(1-2), 167-175.
134. Shen, J.; Wang, Y.; Ping, Q.; Xiao, Y.; Huang, X. Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J. Control. Release, 2009, 137(3), 217-223.
135. Li, X.; Nie, S.F.; Kong, J.; Li, N.; Ju, C.Y.; Pan W.S. controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int. J. Pharm., 2008, 363(1-2), 177-182.
136. Elbashir, S.M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 2001, 411(6836), 494-498.
137. Kim, B.; Tang, Q.; Biswas, P.S.; Xu, J.; Schiffelers, R.M.; Xie, F.Y. Ansari, A.M.; Scaria, P.V.; Woodle, M.C.; Lu, P.; Rouse, B.T. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes e therapeutic strategy for herpetic stromal keratitis. Am. J. Pathol., 2004, 165(6), 2177-2185.
138. Reich, S.J.; Fosnot, J.; Kuroki, A.; Tang, W.; Yang, X.; Maguire, A.M.; Bennett, J.; Tolentino, M.J. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis., 2003, 9, 210-216.
139. Gu, L.; Chen, H.; Tuo, J.; Gao, X.; Chen, L. Inhibition of experimental choroidal neovascularization in mice by anti-VEGFA/VEGFR2 or non-specific siRNA. Exp. Eye Res., 2010, 91(3), 433-439.
140. Wong, V.G.; Hu, M.W.L.; Berger, D.E. Controlled release biocompatible ocular drug delivery implant devices and methods. U.S. Patent 6,331,313, December 18, 2001.
141. Chauhan, A.; Gulsen, D. Ophthalmic drug delivery system. U.S. Patent 7,638,137, December 29, 2009.
142. Peyman, G.A. Delivery of an ocular agent. U.S. Patent 2007/0072933, March 29, 2007.
143. Li, X.; Jasti, B.; Mahalingam, R. Ocular agent delivery systems. U.S. Patent 2008/0132444, January 5, 2008.
144. Peyman, G.A. Drug delivery to the crystalline lens and other ocular structures. U.S. Patent 2006/0229585, October 12, 2006.
145. Loftsson, T.; Stefansson, E. Cyclodextrin nanotechnology for ophthalmic drug delivery. U.S. Patent 2007/0020336, January 25, 2007.
146. Mousa, S.; Block, E. Natural and synthetic sulfur and selenium analogs and polymer conjugated forms thereof for the modulation of angiogenesis. U.S. Patent 2010/0080843, April 1, 2010.
147. Gross, Y.; Herzog, R.; Koevary, S.B. Method and device for ophthalmic administration of active pharmaceutical ingredients. U.S. Patent 2008/0233053, September 25, 2008.
148. Freilich, D. Ophthalmic insert. U.S. Patent 2008/0086101, April 10, 2008.
149. Moses, M.A.; Brem, H.; Langer, R. Advancing the field of drug delivery: taking aim at cancer. Cancer Cell, 2003, 4(5), 337-341.
150. Yasukawa, T.; Ogura, Y.; Sakurai, E.; Tabata, Y.; Kimura, H. Intraocular sustained drug delivery using implantable polymeric devices. Adv. Drug Deliv. Rev., 2005, 57(14), 2033-2046.
151. Shawgo, R.S.; Richards Grayson, A.C.; Li, Y.; Cima, M.J. BioMEMS for drug delivery. Curr. Opin. Solid State Mater. Sci., 2002, 6, 329-334.
152. Prescott, J.H.; Lipka, S.; Baldwin, S.; Sheppard, N.F. Jr.; Maloney, J.M.; Coppeta, J.; Yomtov, B.; Staples, M.A.; Santini, J.T. Jr. Chronic, programmed polypeptide delivery from an implanted, multireservoir microchip device. Nat. Biotechnol., 2006, 24(4), 437-438.
153. Dee, K.C.; Puleo, D.A.; Bizios R. An Introduction to Tissue- Biomaterial Interactions. John Wiley & Sons, inc., Hoboken, NJ, 2002.
154. Sanders, J.E.; Rochefort, J.R. Fibrous encapsulation of single polymer microfibers depends on their vertical dimension in subcu-taneous tissue. J. Biomed. Mater. Res. A., 2003, 67(4), 1181-1187.
155. Davis, E.R. Handbook of Materials in Medical Devices. ASM International, Materials Park, OH, 2003.
156. Required Biocompatibility Training and Toxicology Profiles for Evaluation of Medical Devices. http://www.fda.gov/cdrh/g951.html (Accessed November 25, 2009).
157. Colthurst, M.J.; Williams, R.L.; Hiscott, P.S.; Grierson, I. Biomaterials used in the posterior segment of the eye. Biomaterials, 2000, 21(7), 649-665.
158. Lloyd, A.W.; Faragher, R.G.; Denyer, S.P. Ocular biomaterials and implants. Biomaterials, 2001, 22(8), 769-785.
159. Le Rouic, J.F.; Bettembourg, O.; D'Hermies, F.; Azan, F.; Renard, G.; Chauvaud, D. Late swelling and removal of Miragel buckles: a comparison with silicone indentations. Retina, 2003, 23(5), 641-646.
160. Giordano, G.G.; Refojo, M.F. Biomaterials in Ophthalmology, Human Biomaterial Applications, edited by DL. Wise Di. Trantolo DE. Altobelli, Humana Press, Inc., Totowa, NJ, 1996; pp. 302-317.
161. Ayyala, R.S.; Duarte, J.L.; Sahiner, N. Glaucoma drainage devices: state of the art. Expert Rev. Med. Devices, 2006, 3(4), 509-521.
162. Scribbick, F.W.; Scribbick, A.T. Ophthalmic implants and explants. Emerg. Med. Clin. North Am., 1994, 12(3), 793-800.
163. Ayyala, R.S.; Harman, L.E.; Michelini-Norris, B.; Ondrovic, L.E.; Haller, E.; Margo, C.E.; Stevens, S.X. Comparison of different biomaterials for glaucoma drainage devices. Arch. Ophthalmol., 1999, 117(2), 233-236.
164. Boswell, C.A.; Noecker, R.J.; Mac, M. Snyder, R.W.; Williams, S.K. Evaluation of an aqueous drainage glaucoma device constructed of ePTFE. J. Biomed. Mater. Res., 1999, 48(5), 591-595.
165. Low, S.P.; Voelcker, N.H.; Canham, L.T.; Williams, K.A. The biocompatibility of porous silicon in tissues of the eye. Biomaterials, 2009, 30(15), 2873-2880.
166. Avitabile, T.; Marano, F.; Castiglione, F.; Bucolo, C.; Cro, M.; Ambrosio, L.; Ferrauto, C.; Reibaldi, A. Biocompatibility and biodegradation of intravitreal hyaluronan implants in rabbits. Biomaterial, 2001, 22(3), 195-200.
167. Chan, G.Y.; Hughes, T.C.; McLean, K.M.; McFarland, G.A.; Nguyen, X.; Wilkie, J.S.; Johnson, G. Approaches to improving the biocompatibility of porous perfluoropolyethers for ophthalmic applications. Biomaterials, 2006, 27(8), 1287-1295.